Conference abstractPublished 9 Apr 2019
Multitarget therapies in the context of the aged associated oxidative stress induced cellular and subcellular and vascular hypoperfusion and mitochondrial DNA deletion during the development and maturation of Alzheimer disease: past, present and future
“GALLY” International Biomedical Research Institute Inc., USAUniversity of Atlanta, Atlanta, USARussian Academy of Sciences, Russia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Stroke and arteriosclerosis with neurological consequences such as Alzheimer disease (AD) are two leading causes of ageassociated disability, dementia, and death. AD is now the sixth-leading cause of death in the United States. In the US, AD is estimated to affect 4 million people (rising steeply from <1% of the population aged 65 to 40% of those aged 90) and costs $600 billion per year, which is equivalent to the total cost of stroke, heart disease, and cancer combined. Overall, there are no effective strategies for determining and controlling this devastating disease. Because AD is a multifactorial pathology and the development of new multitarget neuroprotective drugs is promising and attractive.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Alzheimers Disease & Parkinsonism
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Gjumrakch Aliev”